Treatment with a glutathione synthesis inhibitor, buthionine sulfoximine (BSO), decreased glutathione levels and abolished Bcl-2-mediated cisplatin resistance, indicating that Bcl-2-mediated cisplatin resistance in cancer cells is dependent on increased glutathione production [99]. The gene discussed is BCL2; the disease is cancer.